Neurofeedback is emerging as a viable alternative to pharmacological treatments for mental health issues such as ADHD, anxiety, depression, etc., with a market of $1.1B in 2021 and a 7.9% CAGR. The method’s use of messy gel electroencephalography (EEG) electrodes in up to 40 1-hour long in-clinic sessions leads to high rates of patient attrition and hinders scalability. Wearable Sensing (WS) is commercializing high-fidelity, easy-to-use, and comfortable dry electrode EEG headsets that have been enthusiastically adopted by the neurofeedback community. WS will leverage this technology to create BRAINGYM, a neurofeedback solution that consist of: 1) an FDA-approved headset with in-clinic and at-home use designs, 2) integrated Virtual Reality (VR), and 3) an intuitive cloud-based neurofeedback software with patient and physician user portals. BRAINGYM will revolutionize neurofeedback by increasing patient compliance, reducing their costs, and enabling practitioners to treat more patients.